Quantitative RT-PCR (qRT-PCR)

Overview

Reverse-transcription quantitative PCR for measuring mRNA expression levels. Used in the corpus for biomarker validation, clinical diagnostic panel development, and confirmation of expression changes identified by microarray or RNA-seq.

Used by

  • A 13-gene qRT-PCR panel (TERT, IGF2, GJB2, TEK, TIAM1, CXCL12, TOP2A, A2M, PLG, CDKN2A, PDGFRA, MKI67, THBS1) used in HCC to distinguish dysplastic cirrhotic nodules from early HCC; a 3-gene panel (GPC3, LYVE1, survivin/BIRC5) achieves 95% sensitivity and 94% specificity for discriminating high-grade dysplastic nodules from tumors <2 cm PMID:24735922.
  • Used to validate EWS::FLI1 target gene expression (EZH2, IGF1, NGFR, PADI2, DKK2, NR0B1, PRKCB) in transduced heMSCs and siRNA knockdown experiments. PMID:25186949
  • Used to assess CDKN2A status and detect EWSR1-ETS fusion transcripts in Ewing sarcoma samples PMID:25223734
  • Quantitative RT-PCR used to validate gene expression findings in adrenocortical carcinoma PMID:26095796
  • Quantitative RT-PCR used to validate RNA expression results in proteogenomic analysis of ovarian cancer PMID:26200345
  • RT-PCR used to validate MYBL1-NFIB and other MYBL1 fusion transcripts, and to quantify MYB and MYBL1 mRNA expression in all 102 salivary adenoid cystic carcinomas demonstrating mutually exclusive high expression PMID:26631609.
  • Quantitative RT-PCR used to validate MYB and MYB-target gene expression changes following BET bromodomain inhibitor JQ1 treatment in grade-2 and grade-3 ACC primagrafts PMID:26829750
  • qRT-PCR used to quantify DUX4 and ERGalt expression in B-ALL cell lines and patient-derived xenografts in the DUX4/ERG B-ALL subtype study. PMID:27776115
  • Quantitative RT-PCR used to confirm that spautin-1 reduced TRMT10A protein but not mRNA levels, establishing post-transcriptional (proteasomal) regulation PMID:28068672.
  • RT-qPCR used to validate RNA-seq-derived NOL10 cell-cycle signature gene set (DLGAP5, MCM4, KIF20B, DIAPH3, SUV39H1, CENPE, GINS2, HMGB3, CDC6) and to measure NOL10 and USF1 expression changes after CRISPR perturbations and knockdown experiments across DU145, 22Rv1, LNCaP, and PC3 cells PMID:28927585

Notes

  • Appropriate for clinical deployment given low cost and FFPE compatibility; panels must be validated across platforms for cross-center use.
  • The 3-gene HCC panel (GPC3, LYVE1, survivin) provides a practical complement to IHC for small-nodule diagnosis PMID:24735922.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:25186949

This page was processed by crosslinker on 2026-05-14. - PMID:25223734

This page was processed by crosslinker on 2026-05-14. - PMID:26095796

This page was processed by crosslinker on 2026-05-14. - PMID:26200345

This page was processed by crosslinker on 2026-05-14. - PMID:26631609

This page was processed by crosslinker on 2026-05-14. - PMID:26829750

This page was processed by entity-page-writer on 2026-05-15. - PMID:27776115

This page was processed by entity-page-writer on 2026-05-15. - PMID:28068672

This page was processed by wiki-cli on 2026-05-14. - PMID:28927585

This page was processed by wiki-cli on 2026-05-15.